Announcement Under Regulation 30 22 Sep - Jodhpur GST appellate order confirms Rs.71.63 lakh tax, Rs.12.66 lakh penalty and interest for FY20; appeal planned.
Source: Bse
Chemicals stocks · Mid cap · NSE
Coromandel International Limited is an Indian agri-input company, primarily engaged in the manufacturing and marketing of fertilizers (Nutrients segment) and crop protection chemicals (CPC segment). It also offers specialty nutrients and organic fertilizers, serving the agricultural sector across India.
full bear SMA stack · SMA20 -7.2% / mo · MACD + · sector -5.7pp vs Nifty 500 (3M)
Latest FPI flow is positive, but a second consecutive positive fortnight is still required. View sector evidence
Adjusted completed-session prices, rebased to 100
Weak fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend argues for patience, and recent execution is weak.
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Revenue +15.9% · PAT -23.9% YoY
Price trend and sector-relative-strength timing.
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Financial-only signal; management claim evidence is not sufficient yet.
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
PAT -24% YoY · margin compression · Rev +16% YoY · +36% QoQ
| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹8,165 Cr | +15.9% | +36.0% |
| EBITDA | ₹756 Cr | -3.3% | +54.9% |
| Operating margin | 9.0% | -200 bps | +100 bps |
| PAT | ₹382 Cr | -23.9% | +232.2% |
| PAT margin | 4.7% | -245 bps | +276 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Updated 21/10/2026
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Signals are conflicting — long-term trend down. RSI 46. Wait for confirmation.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
U-Score 42 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
Top U-Score contributors and drags from the latest stored fundamentals.
Cyclical companies can look cheapest near peak profits, so IndiaPulse flags value-trap risk separately.
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
12 stored score snapshots. Latest stored move: +0 points.
Business-comparable peers in Chemicals — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Growth engines, risks, management commitments and evidence-backed delivery
Q4 FY26 consolidated revenue grew 20% YoY to ₹6,004 Cr, but PAT plunged 80% YoY to ₹115 Cr due to a sharp decline in Nutrients segment PBIT and exceptional items. Full-year FY26 revenue rose 31% YoY to ₹31,480 Cr, while PAT declined 8% YoY to ₹1,898 Cr.
While full-year revenue growth was strong, the significant Q4 PAT decline and overall margin contraction (EBITDA and PAT) raise concerns. The Nutrients segment's Q4 PBIT drop is a key issue, partially offset by strong performance in the CPC segment, boosted by an acquisition. Exceptional items also impacted Q4.
Consolidated CPC revenue grew 50% YoY in FY26 and 54% YoY in Q4 FY26, with PBIT up 41% and 19% respectively.
Urea sales volume increased 66.6% YoY in FY26 and 42.8% YoY in Q4 FY26 for the Nutrients segment.
Imported NPK+DAP sales volume grew 54.8% YoY in FY26 and 26.1% YoY in Q4 FY26.
NACL Industries Limited became a subsidiary of Coromandel effective August 8, 2025, contributing to consolidated CPC segment growth.
The company reported -₹71 Cr in exceptional items in Q4 FY26 and FY26, impacting PAT.
Nutrients segment PBIT declined 18% YoY in Q4 FY26, despite a 15% increase in sales.
Consolidated EBITDA margin decreased from 9% to 8% in Q4 FY26 and from 11% to 10% in FY26. PAT margin also declined.
Issuer guidance and extracted claims are tracked against later reported outcomes. Treat these as management statements, not IndiaPulse forecasts.
Both quarterly (Q4) and annual (FY) comparisons are essential. Q4 shows recent momentum and specific challenges (e.g., Nutrients PBIT drop, exceptional items), while FY provides a broader view of annual performance and strategic impact (e.g., NACL acquisition).
Q4 FY26: ₹6,004 Cr (+20% YoY); FY26: ₹31,480 Cr (+31% YoY).
Q4 FY26: ₹494 Cr (+16% YoY); FY26: ₹3,232 Cr (+23% YoY).
Q4 FY26: ₹115 Cr (-80% YoY); FY26: ₹1,898 Cr (-8% YoY).
Q4 FY26: 8% (vs 9% Q4 FY25); FY26: 10% (vs 11% FY25).
| Checkpoint | Current evidence | What to verify next |
|---|---|---|
| Nutrients Segment PBIT Trend | Q4 FY26 PBIT down 18% YoY. | Reversal of PBIT decline and margin improvement in the Nutrients segment. |
| Consolidated Margin Trend | FY26 EBITDA margin 10% (vs 11% FY25), PAT margin 6% (vs 9% FY25). | Stabilization and expansion of consolidated EBITDA and PAT margins. |
| Integration of NACL Industries | NACL became a subsidiary in August 2025, boosting CPC segment. | Continued strong performance and synergy realization from the acquired entity. |
Verification checkpoints are IndiaPulse research interpretation, not investment advice.
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 78th percentile of the scored universe and 64th percentile within Chemicals. Main check: results consistency is weak at 54/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
overall median 67 · Chemicals: 64th pctile, median 73 · Mid: 48th pctile, median 76
76 documents have extracted text, but claim history is not strong enough yet.
0 claims extracted · No contradicted claim yet
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Latest exchange and company disclosures found within the past two years.
Source: Bse
Source: Bse
Source: Bse
Source: Bse
Source: Bse
Source: Bse
Source: Bse